LIK066 + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Obese Patients With Non-alcoholic Steatohepatitis (NASH)
Conditions
Obese Patients With Non-alcoholic Steatohepatitis (NASH)
Trial Timeline
Oct 4, 2017 → Nov 14, 2019
NCT ID
NCT03205150About LIK066 + Placebo
LIK066 + Placebo is a phase 2 stage product being developed by Novartis for Obese Patients With Non-alcoholic Steatohepatitis (NASH). The current trial status is completed. This product is registered under clinical trial identifier NCT03205150. Target conditions include Obese Patients With Non-alcoholic Steatohepatitis (NASH).
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03320941 | Phase 2 | Completed |
| NCT03205150 | Phase 2 | Completed |
| NCT03152591 | Phase 2 | Completed |
| NCT03100058 | Phase 2 | Completed |
| NCT02470403 | Phase 2 | Completed |
| NCT01915849 | Phase 1/2 | Completed |
| NCT01407003 | Phase 1/2 | Completed |
Competing Products
9 competing products in Obese Patients With Non-alcoholic Steatohepatitis (NASH)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lorcaserin | Eisai | Phase 1 | 33 |
| Bardoxolone methyl + Placebo | Kyowa Kirin | Phase 1 | 33 |
| Investigational new drug company code: BGS649 + Placebo | Novartis | Phase 2 | 52 |
| Placebo + CT-388 | Roche | Phase 2 | 52 |
| Growth hormone treatment | Pfizer | Pre-clinical | 22 |
| BMS-963272 + Placebo | Bristol Myers Squibb | Phase 1 | 32 |
| ALN-4324 + Placebo | Alnylam Pharmaceuticals | Phase 1/2 | 38 |
| Aleniglipron + Placebo | Structure Therapeutics | Phase 2 | 47 |
| CRB-913 + Placebo | Corbus Pharmaceuticals | Phase 1 | 25 |